{
    "medicine_id": "1e9520e25a64f68a98c41a49d698409f4b9bcd2b",
    "platform_id": "DB09114",
    "metadata": {
        "name": "Exosurf Neonatal Suspension",
        "composition": "Colfosceril palmitate",
        "clinical_particulars": {
            "therapeutic_indications": "Colfosceril palmitate is indicated for the treatment of respiratory distress syndrome RDS in premature infants The official label is referred as a intratracheal suspension for prophylactic treatment of infants of less than 1350 grams of birth weight under risk of developing RDS or in infants with birth weight greater than 1350 grams with pulmonary immaturity or as rescue treatment of infants that already developed RDS L1109 The central feature of RDS is a surfactant deficiency due to lung immaturity This lung condition is more frequently presented due to risk factors like prematurity delayed lung maturation caused by maternal diabetes or male gender or surfactant dysfuntion due to perinatal asphyxia pulmonary infection or delivery without labor T70",
            "contraindications": {
                "disease": "In clinical trials there are reports of pulmonary hemorrhage when colfosceril palmitate is administered in infants with a weight of fewer than 700 grams at birth Another potential risk of the use of colfosceril palmitate is the formation of mucus plugging in the endotracheal tube which can be prevented by performing suction prior to dosing L1109",
                "pregnancy": "NA",
                "machine_ops": "NA",
                "pharmacodynamics": "Colfosceril palmitate has shown to significantly reduce the risk of pneumothoraces pulmonary interstitial emphysema and mortality Unlike naturals surfactants colfosceril palmitate reduces the risk of bronchopulmonary dysplasia intraventricular hemorrhage and patent ductus arteriosus T71 In clinical placebo controlled trials there was a significant reduction in the number of deaths attributed to hyaline membrane disease the incidence of pulmonary air leaks oxygen requirements and mean airway pressure T72 Some reports have indicated a lack of therapeutic effect due to the absence of surfactant protein T73",
                "excipients": "NA",
                "incompatibilities": []
            }
        },
        "revision_date": "2023-05-14"
    }
}